Advertisement

Psychopharmacology

, Volume 189, Issue 3, pp 395–401 | Cite as

The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not β2- or α7-nicotinic acetylcholine receptor subunit knockout mice

  • R. L. Rabenstein
  • B. J. Caldarone
  • M. R. PicciottoEmail author
Original Investigation

Abstract

Rationale

Increases in cholinergic transmission are linked to depression in human subjects and animal models. We therefore examined the effect of decreasing nicotinic acetylcholine receptor (nAChR) activity in tests of antidepressant efficacy using C57BL/6J mice.

Objectives

We determined whether the noncompetitive nAChR antagonist mecamylamine had antidepressant-like effects in the forced swim test (FST) and tail suspension test (TST). These experiments were repeated in mice lacking either the β2- or α7-nAChR subunits to identify the nAChR subunits involved in mediating the antidepressant response to mecamylamine.

Materials and methods

Adult mice on the C57BL/6J background were acutely administered mecamylamine i.p. 30 min before testing in the FST or TST.

Results

A dose–response study showed that mecamylamine significantly decreased immobility time in the TST at the 1.0-mg/kg dose but did not alter baseline locomotor activity. The competitive nAChR antagonist dihydro-β-erythroidine, but not the blood–brain barrier impermeant antagonist hexamethonium, also decreased immobility in the TST. One milligram per kilogram of mecamylamine also significantly decreased time immobile in the FST whereas both β2- and α7-knockout mice were insensitive to the effects of mecamylamine in the FST.

Conclusions

Decreased activity of central nAChRs has antidepressant-like effects in both the TST and FST and these effects are dependent on both β2 and α7 subunits. Therefore, compounds that decrease nAChR activity may be attractive new candidates for development as antidepressants in humans.

Keywords

Antidepressant Forced swim Tail suspension Nicotinic acetylcholine receptor Mecamylamine 

Notes

Acknowledgements

This work was supported by NIH grants DA13334/AA15632, MH77681, and DA00436 and the NARSAD Foster Bam Award.

References

  1. Breslau N (1995) Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 25:95–101PubMedCrossRefGoogle Scholar
  2. Caldarone BJ, Karthigeyan K, Harrist A, Hunsberger JG, Wittmack E, King SL, Jatlow P, Picciotto MR (2003) Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6J mice. Psychopharmacology (Berl) 170:94–101CrossRefGoogle Scholar
  3. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR (2004) High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry 56:657–664PubMedCrossRefGoogle Scholar
  4. Covey LS, Glassman AH, Stetner F (1997) Major depression following smoking cessation. Am J Psychiatry 154:263–265PubMedGoogle Scholar
  5. Covey LS, Glassman AH, Stetner F (1998) Cigarette smoking and major depression. J Addict Dis 17:35–46PubMedCrossRefGoogle Scholar
  6. Crabbe JC, Wahlsten D, Dudek BC (1999) Genetics of mouse behavior: interactions with laboratory environment. Science 284:1670–1672PubMedCrossRefGoogle Scholar
  7. Crawley JN, Paylor R (1997) A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 31:197–211PubMedCrossRefGoogle Scholar
  8. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238–245PubMedCrossRefGoogle Scholar
  9. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571–625PubMedCrossRefGoogle Scholar
  10. Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW (1998) Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 33:113–118PubMedCrossRefGoogle Scholar
  11. Djuric VJ, Dunn E, Overstreet DH, Dragomir A, Steiner M (1999) Antidepressant effect of ingested nicotine in female rats of Flinders resistant and sensitive lines. Physiol Behav 67:533–537PubMedCrossRefGoogle Scholar
  12. Ferguson SM, Brodkin JD, Lloyd GK, Menzaghi F (2000) Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology (Berl) 152:295–303CrossRefGoogle Scholar
  13. Giniatullin R, Nistri A, Yakel JL (2005) Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends Neurosci 28:371–378PubMedCrossRefGoogle Scholar
  14. Gosling JA, Lu TC (1969) Uptake and distribution of some quaternary ammonium compounds in the central nervous system of the rat. J Pharmacol Exp Ther 167:56–62PubMedGoogle Scholar
  15. Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E (1998) Nortriptyline and cognitive–behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55:683–690PubMedCrossRefGoogle Scholar
  16. Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover ED, Sachs DP, Hurt RD (1999) Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 174:173–178PubMedCrossRefGoogle Scholar
  17. Janowsky DS, el-Yousef MK, Davis JM, Hubbard B, Sekerke HJ (1972a) Cholinergic reversal of manic symptoms. Lancet 1:1236–1237PubMedCrossRefGoogle Scholar
  18. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ (1972b) A cholinergic–adrenergic hypothesis of mania and depression. Lancet 2:632–635PubMedCrossRefGoogle Scholar
  19. Killen JD, Fortmann SP, Schatzberg A, Hayward C, Varady A (2003) Onset of major depression during treatment for nicotine dependence. Addict Behav 28:461–470PubMedCrossRefGoogle Scholar
  20. King SL, Marks MJ, Grady SR, Caldarone BJ, Koren AO, Mukhin AG, Collins AC, Picciotto MR (2003) Conditional expression in corticothalamic efferents reveals a developmental role for nicotinic acetylcholine receptors in modulation of passive avoidance behavior. J Neurosci 23:3837–3843PubMedGoogle Scholar
  21. Kos T, Legutko B, Danysz W, Samoriski G, Popik P (2006) Enhancement of antidepressant-like effects but not BDNF mRNA expression by the novel NMDA receptor antagonist neramexane in mice. J Pharmacol Exp TherGoogle Scholar
  22. Laje RP, Berman JA, Glassman AH (2001) Depression and nicotine: preclinical and clinical evidence for common mechanisms. Curr Psychiatry Rep 3:470–474PubMedGoogle Scholar
  23. Malin DH, Lake JR, Schopen CK, Kirk JW, Sailer EE, Lawless BA, Upchurch TP, Shenoi M, Rajan N (1997) Nicotine abstinence syndrome precipitated by central but not peripheral hexamethonium. Pharmacol Biochem Behav 58:695–699PubMedCrossRefGoogle Scholar
  24. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer’s disease: a pilot study. Psychopharmacology (Berl) 95:171–175Google Scholar
  25. O’Neil MF, Moore NA (2003) Animal models of depression: are there any? Hum Psychopharmacol 18:239–254PubMedCrossRefGoogle Scholar
  26. Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, Dani JA, Patrick JW, Beaudet AL (1997) Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 17:9165–9171PubMedGoogle Scholar
  27. Overstreet DH (1993) The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev 17:51–68PubMedCrossRefGoogle Scholar
  28. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, Le Novere N, Vincent P, Pich EM, Brulet P, Changeux JP (1995) Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374:65–67PubMedCrossRefGoogle Scholar
  29. Picciotto MR, Caldarone BJ, King SL, Zachariou V (2000) Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22:451–465PubMedCrossRefGoogle Scholar
  30. Picciotto MR, Brunzell DH, Caldarone BJ (2002) Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 13:1097–1106PubMedCrossRefGoogle Scholar
  31. Pomerleau OF, Pomerleau CS (1984) Neuroregulators and the reinforcement of smoking: towards a biobehavioral explanation. Neurosci Biobehav Rev 8:503–513PubMedCrossRefGoogle Scholar
  32. Popik P, Kozela E, Krawczyk M (2003) Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Br J Pharmacol 139:1196–1202PubMedCrossRefGoogle Scholar
  33. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336PubMedGoogle Scholar
  34. Salin-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Colin R (1995) Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology (Berl) 121:476–479CrossRefGoogle Scholar
  35. Semba J, Mataki C, Yamada S, Nankai M, Toru M (1998) Antidepressant-like effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry 43:389–391PubMedCrossRefGoogle Scholar
  36. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR (2002) Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7:525–535PubMedCrossRefGoogle Scholar
  37. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85:367–370CrossRefGoogle Scholar
  38. Thierry B, Steru L, Simon P, Porsolt RD (1986) The tail suspension test: ethical considerations. Psychopharmacology (Berl) 90:284–285Google Scholar
  39. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E Jr, Janowsky DS, Kling MA (1999) Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) 142:193–199CrossRefGoogle Scholar
  40. Wahlsten D, Metten P, Phillips TJ, Boehm SL 2nd, Burkhart-Kasch S, Dorow J, Doerksen S, Downing C, Fogarty J, Rodd-Henricks K, Hen R, McKinnon CS, Merrill CM, Nolte C, Schalomon M, Schlumbohm JP, Sibert JR, Wenger CD, Dudek BC, Crabbe JC (2003) Different data from different labs: lessons from studies of gene–environment interaction. J Neurobiol 54:283–311PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • R. L. Rabenstein
    • 1
    • 2
  • B. J. Caldarone
    • 2
  • M. R. Picciotto
    • 1
    • 2
    Email author
  1. 1.Interdepartmental Neuroscience ProgramYale University School of MedicineNew HavenUSA
  2. 2.Department of PsychiatryYale University School of MedicineNew HavenUSA

Personalised recommendations